The global primary cells market size is projected to reach USD 1,613 million by 2025 from USD 970 million in 2020, at a CAGR of 10.7% during the forecast period. Growth in the primary cells market is mainly driven by factors such as increasing cancer research, the advantages of primary human cells over cell lines, the increasing demand for monoclonal antibodies, rapid growth in the biotechnology & biopharmaceutical industries, and growing focus on personalized medicine. Biomedical research using primary cells in 3D cultures is also expected to provide a wide range of growth opportunities for players in the market. On the other hand, concerns regarding primary cell culture contamination are expected to limit market growth to a certain extent in the coming years.
The major players in this market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza (Switzerland), Cell Biologics, Inc. (US), PromoCell GmbH (Germany), HemaCare Corporation (US), ZenBio, Inc. (US), STEMCELL Technologies, Inc. (Canada), Corning Incorporated (US), AllCells (US), American Type Culture Collection (US), Axol Bioscience Ltd. (UK), iXCells Biotechnologies (US), Neuromics (US), StemExpress (US), BioIVT (US), ScienCell Research Laboratories, Inc. (US), PPA Research Group, Inc. (US), Creative Bioarray (US), BPS Bioscience, Inc. (US), Epithelix Sārl (Switzerland), ReachBio LLC (US), AcceGen (US), Sekisui XenoTech, LLC (US), and Biopredic International (France).
To know about the assumptions considered for the study download the pdf brochure
Thermo Fisher Scientific accounted for the largest share of the primary cells market in 2019. The company maintains its leading position in the primary cells market due to its well-established product portfolio. The company adopted partnerships and expansions as key strategies to strengthen its position as well as expand its product portfolio. Thermo Fisher Scientific will be investing more than USD 475 million in new capabilities at its St. Louis site (Missouri, US) to expand its biologics development & manufacturing, cell & gene therapy, and drug product development capacity. Such developments have helped the company enhance its visibility in the primary cells market.
In 2019, Merck KGaA accounted for the second-largest share of the primary cells market. The company has a strong foothold in this market with its extensive range of primary cell products. To maintain its leading position in the primary cells market, the company focuses on organic growth strategies such as expansions. In March 2019, the company opened a new M Lab Collaboration Center in Molsheim, France. This expansion will provide its pharmaceutical, and biotechnology customers access to its Life Science product portfolio and technical expertise. The company also focuses on enhancing its presence in the high-growth Asian region to increase its market share and revenue. In the last three years, the company has opened life science centers in China, India, South Korea, and Singapore.
Lonza (Switzerland) is engaged in providing chemical and biotechnology ingredients and custom manufacturing services to the pharmaceutical, healthcare, and life science industries. The company operates through two divisions, namely, Specialty Ingredients and Pharma, Biotech & Nutrition. Through its Pharma, Biotech & Nutrition segment, the company offers human and animal primary cells. The company adopted product launches as a key strategy to strengthen its position and expand its product portfolio. In 2018, Lonza expanded its primary cells portfolio and added hepatic stellate cells, Kupffer cells, and liver-derived endothelial cells to its hepatocytes range portfolio.
Primary Cells Market by Origin (Human Primary Cells, Animal Primary Cells), Type (Hematopoietic, Dermatocytes, Gastrointestinal, Hepatocytes, Lung, Renal, Musculoskeletal, Heart), End User, Region - Global Forecast to 2025
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE